TAO Synergies (TAOX) Net Equity Issued and Repurchased (2025)
TAO Synergies' (TAOX) quarterly Net Equity Issued and Repurchased came in at $5.0 million in Q4 2025, up 2740.0% quarter-over-quarter from -$190000.0 in Q3 2025.
Powered by 
Analysis
TAO Synergies (TAOX) Net Equity Issued and Repurchased (2025) Analysis & Trends
TAO Synergies (TAOX) has reported Net Equity Issued and Repurchased for 1 consecutive years, with $5.0 million the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.40 Bn | 197.42 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn | 9.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.13 Bn | 124.28 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.53 Bn | 74.53 Bn | 3.93 Bn | 49.20 Mn |
| 5 | Argenx Se | 61.72 Bn | 56.54 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.67 Bn | 49.53 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.00 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.03 Bn | 30.03 Bn | 1.16 Mn | - |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | - |